ALSO NOTED: Kickback investigators focus on docs; GSK outsourcing digs into U.K. payroll;

> Fresh off their successful investigation into device makers' payments to doctors--which led to a total of $310 million in fines and ongoing disclosure agreements--the feds are turning to the other side of the table. Investigators now plan to target doctors for soliciting those kickbacks or bribes. Report

> GlaxoSmithKline told workers at its Ulverston, U.K., plant were told that their jobs were at risk as the company outsources some of their functions; some 330 jobs will be eliminated at the plant, which now employs 537. Report

> Sun Pharmaceutical got the FDA nod for its generic form of Tessalon, a Forest Laboratories cough medicine. Report

> A new survey shows that pharma's medical affairs departments aren't reporting to marketing as much as they did in the past; in 2002, 43 percent of medical affairs units were under the marketing umbrella, but now only 7 percent are. Report

And Finally... Eye on FDA has an interview with former FDA chief David Kessler, who presided over the agency "during much happier times." Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.